{"id":"hydroxycarbamide-tablets","safety":{"commonSideEffects":[{"rate":null,"effect":"Myelosuppression (anemia, leukopenia, thrombocytopenia)"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Elevated uric acid levels"},{"rate":null,"effect":"Skin hyperpigmentation"},{"rate":null,"effect":"Peripheral neuropathy"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Hydroxycarbamide (hydroxyurea) is a ribonucleotide reductase inhibitor that decreases DNA synthesis and cell proliferation. In sickle cell disease, it increases fetal hemoglobin (HbF) production, which inhibits polymerization of sickle hemoglobin and reduces vaso-occlusive crises. It also has cytoreductive effects useful in myeloproliferative disorders.","oneSentence":"Hydroxycarbamide inhibits ribonucleotide reductase, reducing deoxynucleotide synthesis and promoting fetal hemoglobin production while decreasing sickling and hemolysis.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:55:14.269Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Sickle cell disease"},{"name":"Chronic myeloid leukemia"},{"name":"Polycythemia vera"},{"name":"Essential thrombocythemia"}]},"trialDetails":[{"nctId":"NCT06079879","phase":"PHASE3","title":"A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-12-31","conditions":"Essential Thrombocythemia","enrollment":340},{"nctId":"NCT07033598","phase":"PHASE2","title":"Pacritinib vs. Hydroxyurea in Advanced Proliferative Chronic Myelomonocytic Leukemia","status":"RECRUITING","sponsor":"Theradex","startDate":"2026-01-01","conditions":"Leukemia, Myelomonocytic, Chronic","enrollment":66},{"nctId":"NCT07232290","phase":"PHASE2","title":"Phase IIa Study on Flonoltinib Maleate Tablets in the Treatment of Patients With Polycythemia Vera","status":"RECRUITING","sponsor":"Chengdu Zenitar Biomedical Technology Co., Ltd","startDate":"2025-09-23","conditions":"Polycythemia Vera (PV)","enrollment":60},{"nctId":"NCT05020652","phase":"PHASE2","title":"A Clinical Trial of TQ05105 Tablets in the Treatment of Moderate and High Risk Myelofibrosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2021-11-11","conditions":"Moderate and High Risk Myelofibrosis","enrollment":107},{"nctId":"NCT03013998","phase":"PHASE1, PHASE2","title":"Study of Biomarker-Based Treatment of Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"Beat AML, LLC","startDate":"2016-11","conditions":"Previously Untreated Relapsed Refractory Acute Myeloid Leukemia","enrollment":3000},{"nctId":"NCT00726232","phase":"PHASE2","title":"Study to Determine the Safety and Efficacy of INCB018424 in Patients With Polycythemia Vera or Essential Thrombocythemia","status":"TERMINATED","sponsor":"Incyte Corporation","startDate":"2008-08-20","conditions":"Myeloproliferative Neoplasm (MPN)","enrollment":73},{"nctId":"NCT04562870","phase":"PHASE2","title":"A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants With Previously Treated Myelofibrosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Karyopharm Therapeutics Inc","startDate":"2021-03-17","conditions":"Myelofibrosis","enrollment":112},{"nctId":"NCT04229979","phase":"PHASE3","title":"Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sellas Life Sciences Group","startDate":"2021-02-08","conditions":"Acute Myeloid Leukemia","enrollment":127},{"nctId":"NCT05953584","phase":"PHASE2","title":"A Phase 2 Open-label Study to Evaluate the Activity of Etavopivat on Transcranial Doppler Velocities in Pediatric Patients With Sickle Cell Disease Who Are at Increased Risk for Primary Stroke","status":"RECRUITING","sponsor":"Forma Therapeutics, Inc.","startDate":"2023-06-20","conditions":"Sickle Cell Disease","enrollment":27},{"nctId":"NCT06578507","phase":"PHASE2","title":"Pharmacokinetics, Efficacy and Safety of Twice Daily Dosing Regimen of Hydroxycarbamide Dispersible Tablets in Children With Sickle Cell Disease","status":"RECRUITING","sponsor":"Theravia","startDate":"2025-01-21","conditions":"Sickle Cell Disease","enrollment":50},{"nctId":"NCT03860844","phase":"PHASE2","title":"Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia","status":"TERMINATED","sponsor":"Sanofi","startDate":"2019-08-06","conditions":"Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia","enrollment":67},{"nctId":"NCT03806452","phase":"PHASE2","title":"SIKAMIC (SIklos on Kidney Function and AlbuMInuria Clinical Trial)","status":"COMPLETED","sponsor":"Theravia","startDate":"2019-05-28","conditions":"Sickle Cell Disease","enrollment":86},{"nctId":"NCT04126681","phase":"PHASE2","title":"A Pivotal Study of HQP1351 in Patients With Chronic Myeloid Leukemia in Chronic Phase","status":"COMPLETED","sponsor":"Ascentage Pharma Group Inc.","startDate":"2019-10-21","conditions":"Chronic Myeloid Leukemia, Chronic Phase","enrollment":144},{"nctId":"NCT06606886","phase":"PHASE4","title":"Effects of Hydroxyurea and Metformin in Transfusion Dependent Beta-Thalassemia","status":"RECRUITING","sponsor":"Bahria University","startDate":"2024-09-16","conditions":"Transfusion Dependent Beta-thalassemia","enrollment":96},{"nctId":"NCT01657682","phase":"PHASE2","title":"A Phase II Study of Crenolanib in Relapsed/Refractory Acute Myeloid Leukemia Patients With FLT3 Activating Mutations","status":"COMPLETED","sponsor":"Arog Pharmaceuticals, Inc.","startDate":"2012-10","conditions":"Acute Myeloid Leukemia With FLT3 Activating Mutations That Has Relapsed or Been Refractory After One or More Prior Therapies","enrollment":56},{"nctId":"NCT04617028","phase":"PHASE3","title":"Jaktinib Versus Hydroxycarbamide in Subjects With Intermediate-2 or High-risk Myelofibrosis","status":"COMPLETED","sponsor":"Suzhou Zelgen Biopharmaceuticals Co.,Ltd","startDate":"2021-02-05","conditions":"Myelofibrosis","enrollment":105},{"nctId":"NCT02101268","phase":"PHASE3","title":"Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF","status":"COMPLETED","sponsor":"Sierra Oncology LLC - a GSK company","startDate":"2014-06-19","conditions":"Primary Myelofibrosis (PMF), Post-polycythemia Vera (Post-PV), Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)","enrollment":156},{"nctId":"NCT02088541","phase":"PHASE2","title":"Selinexor (KPT-330) in Older Patients With Relapsed AML","status":"COMPLETED","sponsor":"Karyopharm Therapeutics Inc","startDate":"2014-03","conditions":"Acute Myeloid Leukemia (AML)","enrollment":317},{"nctId":"NCT05025072","phase":"PHASE1","title":"A Bioequivalence Study to Compare the Pharmacokinetics of Two Formulations of Siklos® in Healthy Volunteers","status":"COMPLETED","sponsor":"Theravia","startDate":"2021-08-22","conditions":"Healthy Volunteers","enrollment":28},{"nctId":"NCT02962388","phase":"PHASE2, PHASE3","title":"The Ruxolitinib Versus Best Available Therapy Trial in Patients With High Risk ET in Second Line","status":"TERMINATED","sponsor":"French Innovative Leukemia Organisation","startDate":"2017-01-03","conditions":"Essential Thrombocythemia","enrollment":13},{"nctId":"NCT04301336","phase":"PHASE2, PHASE3","title":"Different Treatment Modalities in the Management of the Painful Crisis in Pediatric Sickle- Cell Anemia","status":"COMPLETED","sponsor":"Beni-Suef University","startDate":"2019-11-01","conditions":"Vaso-occlusive Crisis, Sickle Cell Disease, Sickle Cell Anemia in Children","enrollment":350},{"nctId":"NCT02042222","phase":"EARLY_PHASE1","title":"Novel Dose Escalation to Predict Treatment With Hydroxyurea","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2013-10","conditions":"Sickle Cell Disease","enrollment":70},{"nctId":"NCT03128515","phase":"PHASE3","title":"Optimizing Hydroxyurea Therapy in Children With SCA In Malaria Endemic Areas","status":"COMPLETED","sponsor":"Indiana University","startDate":"2017-07-26","conditions":"Sickle Cell Anemia, Sickle Cell Disease, Malaria","enrollment":187},{"nctId":"NCT02292446","phase":"PHASE3","title":"Expanded Treatment Protocol (ETP) of Ruxolitinib in Patients With Polycythemia Vera Who Were Hydroxyurea Resistant or Intolerant and for Whom no Treatment Alternatives Was Available.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2014-11-21","conditions":"Polycythemia Vera","enrollment":161},{"nctId":"NCT01259856","phase":"PHASE3","title":"Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET)","status":"COMPLETED","sponsor":"Ronald Hoffman","startDate":"2011-09","conditions":"High Risk Polycythemia Vera, High Risk Essential Thrombocythemia","enrollment":168},{"nctId":"NCT01243944","phase":"PHASE3","title":"Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial)","status":"COMPLETED","sponsor":"Incyte Corporation","startDate":"2010-10-27","conditions":"Polycythemia Vera","enrollment":222},{"nctId":"NCT01976416","phase":"PHASE3","title":"Novel Use Of Hydroxyurea in an African Region With Malaria","status":"COMPLETED","sponsor":"Indiana University","startDate":"2014-09","conditions":"Sickle Cell Anemia, Sickle Cell Disease, Malaria","enrollment":208},{"nctId":"NCT01632904","phase":"PHASE3","title":"Randomized Switch Study From Hydroxyurea to Ruxolitinib for RELIEF of Polycythemia Vera Symptoms: The Relief Study","status":"COMPLETED","sponsor":"Incyte Corporation","startDate":"2012-06","conditions":"Polycythemia Vera","enrollment":110},{"nctId":"NCT03293641","phase":"NA","title":"Zinc Supplementation in Children With Sickle Cell Disease in Western Kenya","status":"COMPLETED","sponsor":"Lucas Otieno Tina, MD MSc","startDate":"2016-05-20","conditions":"Sickle Cell Disease, Zinc Deficiency, Infection","enrollment":40},{"nctId":"NCT02957760","phase":"PHASE2","title":"Prevention of Retinal Non-perfusion in Central Retinal Vein Occlusion by Hydroxycarbamide Treatment.","status":"UNKNOWN","sponsor":"Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts","startDate":"2015-12","conditions":"Central Retinal Vein Occlusion, Non-Ischemic","enrollment":30},{"nctId":"NCT00333840","phase":"PHASE3","title":"Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2000-06","conditions":"Chronic Myelogenous Leukemia","enrollment":1106},{"nctId":"NCT00040677","phase":"PHASE2","title":"A Study of the Efficacy and Safety of ICA-17043 (With or Without Hydroxyurea) in Patients With Sickle Cell Anemia.","status":"COMPLETED","sponsor":"Icagen","startDate":"2002-02","conditions":"Sickle Cell Disease, Sickle Cell Anemia","enrollment":90},{"nctId":"NCT00290771","phase":"PHASE2","title":"Efficacy and Safety of Imatinib Mesylate Plus Hydroxyurea (HU) in Patients With Recurrent Glioblastoma Multiforme (GBM)","status":"TERMINATED","sponsor":"Novartis","startDate":"2006-02","conditions":"Recurrent Glioblastoma Multiforme (GBM)","enrollment":231},{"nctId":"NCT00154375","phase":"PHASE3","title":"Study of Imatinib Mesylate in Combination With Hydroxyurea Versus Hydroxyurea Alone as an Oral Therapy in Patients With Temozolomide Resistant Progressive Glioblastoma","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2004-10","conditions":"Glioblastoma Multiforme, Astrocytoma","enrollment":240},{"nctId":"NCT00809042","phase":"PHASE2","title":"Combination Therapy of Hydroxyurea With L-Carnitine and Magnesium Chloride in Thalassemia Intermedia","status":"COMPLETED","sponsor":"Shiraz University of Medical Sciences","startDate":"2007-06","conditions":"β-Thalassemia Intermedia","enrollment":120}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":25,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Hydroxycarbamide Tablets","genericName":"Hydroxycarbamide Tablets","companyName":"Suzhou Zelgen Biopharmaceuticals Co.,Ltd","companyId":"suzhou-zelgen-biopharmaceuticals-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Hydroxycarbamide inhibits ribonucleotide reductase, reducing deoxynucleotide synthesis and promoting fetal hemoglobin production while decreasing sickling and hemolysis. Used for Sickle cell disease, Chronic myeloid leukemia, Polycythemia vera.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}